<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gene test interpretation: &lt;i&gt;HBA1 &lt;/i&gt;and &lt;i&gt;HBA2 &lt;/i&gt;(alpha globin genes)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gene test interpretation:
       <i>
        HBA1
       </i>
       and
       <i>
        HBA2
       </i>
       (alpha globin genes)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gene test interpretation:
        <i>
         HBA1
        </i>
        and
        <i>
         HBA2
        </i>
        (alpha globin genes)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elliott P Vichinsky, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael R DeBaun, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Louise Wilkins-Haug, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 08, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2847124957">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This monograph discusses implications of a genetic test result for alpha globin genes (
         <em>
          HBA1
         </em>
         and
         <em>
          HBA2
         </em>
         ). Pathogenic variants (often deletions) in these genes cause alpha thalassemia.
        </p>
        <p>
         Alpha globin gene testing cannot identify beta thalassemia or other conditions affecting beta globin such as sickle cell disease.
        </p>
        <p>
         Indications for testing and clinical care of the tested individual are discussed separately in UpToDate [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2186944119">
         <span class="h2">
          How to read the report
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Accuracy
         </strong>
         – Confirm the test was performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified (or other nationally certified) laboratory  (
         <a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genotype
         </strong>
         – Determine whether testing involved alpha globin gene sequencing or a panel of variants. Some laboratories test for selected common variants, which may be sufficient in some cases and insufficient in others.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical correlation
         </strong>
         – Review (or obtain) a complete blood count (CBC). Review the red blood cell (RBC) indices, especially mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH). Determine whether protein-based hemoglobinopathy testing was performed. (See
         <a class="local">
          'Laboratory/diagnostic confirmation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Determine why testing was done and whether results are sufficient for the indication.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reproductive counseling may require more definitive DNA-based diagnosis to determine the risk to offspring and the need for partner testing. (See
         <a class="local">
          'Reproductive counseling and testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Consultation with a genetics expert may be required if severe disease is suspected or reproductive counseling is not straightforward. (See
         <a class="local">
          'Settings for alpha globin testing'
         </a>
         below and
         <a class="local">
          'Locating a specialist'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1088360707">
         <span class="h2">
          Alpha thalassemia genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemoglobin (Hb) is a tetramer of two alpha globin chains and two beta globin chains.
        </p>
        <p>
         Alpha thalassemias are caused by pathogenic variants in the alpha globin genes, leading to reduced alpha globin production [
         <a href="#rid2">
          2
         </a>
         ]. There are four functional alpha globin genes (two distinct, adjacent genes in the alpha globin gene cluster inherited from each parent)  (
         <a class="graphic graphic_figure graphicRef65642" href="/z/d/graphic/65642.html" rel="external">
          figure 1
         </a>
         ). Any number of alpha globin genes from one to four may be affected. The more alpha chains affected, the more severe the alpha thalassemia syndrome. Although beta thalassemia may be more familiar, alpha thalassemia variants are more prevalent worldwide [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Alpha
         <sup>
          0
         </sup>
         variants (deletional variants) abolish alpha globin production; alpha
         <sup>
          +
         </sup>
         variants (non-deletional variants, sometimes designated a
         <sup>
          ND
         </sup>
         ) produce some alpha globin but less than normal [
         <a href="#rid3">
          3
         </a>
         ]. While some alpha
         <sup>
          +
         </sup>
         variants are mild, others can be as severe or worse than a deletional variant.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alpha
         </strong>
         <strong>
          <sup>
           0
          </sup>
         </strong>
         <strong>
          variants
         </strong>
         – Often delete an entire alpha globin gene cluster.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alpha
         </strong>
         <strong>
          <sup>
           +
          </sup>
         </strong>
         <strong>
          variants
         </strong>
         – Alter one or a few nucleotides. Hemoglobin Constant Spring (Hb CS) is a common non-deletional variant, caused by a mutation of the terminal codon in the alpha2 globin gene. (See
         <a class="medical medical_review" href="/z/d/html/7127.html" rel="external">
          "Hemoglobin variants including Hb C, Hb D, and Hb E", section on 'Hb Constant Spring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Alpha globin production begins in utero  (
         <a class="graphic graphic_figure graphicRef65642" href="/z/d/graphic/65642.html" rel="external">
          figure 1
         </a>
         ). In the fetus, alpha globin pairs with gamma globin to make fetal hemoglobin (Hb F); beta globin production begins after birth. Thus, alpha globin variants manifest in utero, whereas beta globin variants manifest after six months of age. (See
         <a class="medical medical_review" href="/z/d/html/7072.html" rel="external">
          "Structure and function of normal hemoglobins"
         </a>
         .)
        </p>
        <p>
         The ratio of alpha and beta chains must be closely matched. If one type of chain is in excess, it will form precipitates within RBCs or RBC precursors in the bone marrow. These precipitated Hbs include Hb Barts (tetramers of gamma globin) and Hb H (tetramers of beta globin). These abnormal Hbs raise the Hb level but are functionally useless because they do not transport oxygen. The precipitates promote hemolysis. (See
         <a class="local">
          'Clinical features'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1036394424">
         <span class="h1">
          CLINICAL
         </span>
        </p>
        <p class="headingAnchor" id="H1551264590">
         <span class="h2">
          Settings for alpha globin testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic testing may be appropriate for:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diagnosis of alpha thalassemia. (See
         <a class="local">
          'Alpha thalassemia genetics'
         </a>
         above and
         <a class="local">
          'Clinical features'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reproductive testing (patient, partner, and/or fetus) and counseling. (See
         <a class="local">
          'Reproductive counseling and testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing the first-degree relative(s) of an individual with alpha thalassemia or an alpha thalassemia carrier state. (See
         <a class="local">
          'Relatives'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2675289482">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical features range from an asymptomatic carrier state to death in utero, depending on the number of alpha globin genes affected and whether the variants are deletional or non-deletional. (See
         <a class="local">
          'Alpha thalassemia genetics'
         </a>
         above.)
        </p>
        <p>
         These are summarized in the table  (
         <a class="graphic graphic_table graphicRef115337" href="/z/d/graphic/115337.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          One
         </strong>
         <strong>
          alpha thalassemia gene
         </strong>
         – Individuals with a single alpha gene variant/deletion (alpha thalassemia minima or silent carrier) are asymptomatic without any laboratory changes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Two
         </strong>
         <strong>
          alpha thalassemia genes
         </strong>
         – Individuals with two alpha gene variants/deletions (alpha thalassemia minor or alpha thalassemia trait) are asymptomatic. They may have mild microcytic anemia or microcytosis without anemia. Hemoglobin (Hb) is decreased by approximately 1 g/dL; it may decrease further during pregnancy. Two possible genotypes are heterozygosity for an alpha
         <sup>
          0
         </sup>
         genotype (aa/--) or compound heterozygosity for an alpha
         <sup>
          +
         </sup>
         genotype (a-/a-). These generally do not affect the individual's clinical status, but they may be important for reproductive counseling. (See
         <a class="local">
          'Reproductive counseling and testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Three alpha thalassemia genes
         </strong>
         – Hb H disease refers to three alpha gene deletions (a-/--) or variants such as (a-/-a
         <sup>
          CS
         </sup>
         ). Hb H is a tetramer of beta globin. The Constant Spring (CS) variant is discussed above. (See
         <a class="local">
          'Alpha thalassemia genetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals with deletional Hb H disease have mild to moderate anemia and occasionally require transfusions. Splenomegaly and pigment gallstones are common. Anemia can be exacerbated by common viral diseases and exposure to oxidant drugs, with sudden transient transfusion requirement.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals with non-deletional Hb H disease such as (a-/-a
         <sup>
          CS
         </sup>
         ) have more severe anemia but less microcytosis. They can require transfusions in utero or at birth; some may require transfusions after birth. Some infants with Hb CS develop marked splenomegaly and severe symptoms requiring long-term chronic transfusions; up to 20 percent of patients with Hb CS require transfusions and splenectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals with three alpha thalassemia gene variants may have ineffective erythropoiesis and increased iron absorption and may develop transfusional or non-transfusional iron overload. (See
         <a class="medical medical_review" href="/z/d/html/7118.html" rel="external">
          "Management of thalassemia", section on 'Regular transfusions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7118.html" rel="external">
          "Management of thalassemia", section on 'Assessment of iron stores and initiation of chelation therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Four alpha thalassemia genes
         </strong>
         – Variants/deletion of all four alpha globin genes (--/--) causes alpha thalassemia major, the most severe form of alpha thalassemia. Most of the circulating Hb is Hb Barts, which does not transport oxygen. These individuals develop hydrops fetalis and typically die in utero unless they receive intrauterine transfusions. After birth, they require chronic transfusions with chelation therapy. Allogeneic hematopoietic stem cell transplant (HSCT) is potentially curative. (See
         <a class="medical medical_review" href="/z/d/html/131582.html" rel="external">
          "Alpha thalassemia major: Prenatal and postnatal management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3037681124">
         <span class="h2">
          Laboratory/diagnostic confirmation
         </span>
         <span class="headingEndMark">
          —
         </span>
         All individuals with suspected alpha thalassemia should have a complete blood count (CBC) and review of the red blood cell (RBC) indices. Hemolysis testing is appropriate if there is anemia or reticulocytosis  (
         <a class="graphic graphic_table graphicRef126234" href="/z/d/graphic/126234.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CBC
         </strong>
         – Mean corpuscular volume (MCV) &lt;80 fL and/or mean corpuscular hemoglobin (MCH) &lt;27 is consistent with alpha thalassemia, regardless of whether anemia is present, but they are not diagnostic, as they can also occur in iron deficiency and other disorders  (
         <a class="graphic graphic_algorithm graphicRef140056" href="/z/d/graphic/140056.html" rel="external">
          algorithm 1
         </a>
         ). Typically, the RBC count is
         <strong>
          increased
         </strong>
         in thalassemia and decreased in iron deficiency. (See
         <a class="medical medical_review" href="/z/d/html/4432.html" rel="external">
          "Microcytosis/Microcytic anemia", section on 'Approach to the evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Iron studies
         </strong>
         – Individuals being evaluated for thalassemia should have iron studies to exclude or diagnose iron deficiency and to evaluate iron overload.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Iron deficiency causes microcytic anemia and can interfere with protein-based hemoglobin analysis  (
         <a class="graphic graphic_algorithm graphicRef140056" href="/z/d/graphic/140056.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Iron studies (list of available tests)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Iron overload is common in thalassemia. (See
         <a class="medical medical_review" href="/z/d/html/7116.html" rel="external">
          "Diagnosis of thalassemia (adults and children)", section on 'Iron overload'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Protein or DNA-based hemoglobin analysis
         </strong>
         – Diagnostic confirmation can be done by protein-based or molecular testing [
         <a href="#rid3">
          3,4
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Protein-based testing such as high-performance liquid chromatography (HPLC) or electrophoresis (gel-based or capillary) can confirm alpha thalassemia if Hb H (or Hb Barts) is present. HPLC or capillary electrophoresis are preferred; they are more accurate and quantitative. Protein-based methods may detect Hb A2 and Hb F, which can be supportive but less specific. Hb A2 &gt;4 percent is diagnostic of beta thalassemia; low Hb A2 is suggestive of alpha thalassemia or iron deficiency. (See
         <a class="medical medical_review" href="/z/d/html/13941.html" rel="external">
          "Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Protein chemistry methods'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Molecular (DNA) testing provides the specific genotype. Alpha thalassemia minima (single alpha globin gene affected) requires molecular testing. (See
         <a class="medical medical_review" href="/z/d/html/13941.html" rel="external">
          "Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Molecular genetic (DNA-based) methods'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hb analysis may be omitted in some cases, such as individuals with normal CBC who are not considering childbearing.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3285916782">
         <span class="h2">
          Interventions
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          Folic acid
         </a>
         – All individuals with chronic hemolysis are advised to take folic acid (typical dose, 1 mg daily; higher doses prior to conception and during pregnancy). This may be reasonably omitted in individuals with a folate-replete diet who are not attempting to conceive.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transfusions
         </strong>
         – Transfusions may be needed for severe anemia, transient aplastic crisis, or other bone marrow stressors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cholecystectomy/splenectomy
         </strong>
         – Cholecystectomy may be necessary in Hb H disease due to pigment gallstones. Hb H disease with a non-deletional variant often requires splenectomy to improve Hb levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chelation
         </strong>
         – As Hb H patients age, they develop iron overload even without transfusions; they require monitoring and potentially iron chelation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          PK activator
         </strong>
         –
         <a class="drug drug_general" data-topicid="135030" href="/z/d/drug information/135030.html" rel="external">
          Mitapivat
         </a>
         is a small molecule activator of pyruvate kinase (PK) that increased hemoglobin in a small study; further trials are ongoing. (See
         <a class="medical medical_review" href="/z/d/html/7118.html" rel="external">
          "Management of thalassemia", section on 'Mitapivat'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alpha thalassemia major
         </strong>
         – Alpha thalassemia major requires aggressive treatment, with transfusions in utero followed by lifelong transfusions and iron chelation. Hematopoietic stem cell transplantation (HSCT) can be curative; in utero fetal HSCT is under investigation. The possibility of HSCT after birth should be discussed. (See
         <a class="medical medical_review" href="/z/d/html/131582.html" rel="external">
          "Alpha thalassemia major: Prenatal and postnatal management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1648008204">
         <span class="h1">
          REPRODUCTIVE COUNSELING AND TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with alpha thalassemia should be offered age-appropriate reproductive counseling. Those planning to conceive should be offered counseling and partner testing. Relevant information is available at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffetus.ucsf.edu%2Fuploads%2FFTC-prenatal_screening_for_thalassemia.pdf&amp;token=VGX9j%2FJCMa0KF1UFx8Q3IBsmniADcrhYCRV4CbV44BAJ9wUGCKCT1VcZRyd%2BjDR%2FXlc2sOR7mRox8YCocZ8NW%2B4iKNqq%2BZqsVvS5fmloMgE%3D&amp;TOPIC_ID=138739" target="_blank">
          UCSF website
         </a>
         [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Alpha thalassemia variants are prevalent in individuals with ancestry from Southern China, Malaysia, Thailand, and Africa. However, due to migration, alpha thalassemia variants can be present in individuals with any ancestry.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alpha thalassemia-1 trait (two alpha gene deletions in cis; aa/--) is more common in individuals with ancestry from Southern China, Malaysia, and Thailand; these individuals are at greater risk for having a pregnancy with hydrops fetalis (Hb Barts).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals of African ancestry typically carry the alpha thalassemia-2 trait (two alpha gene deletions in trans; a-/a-). The pathogenic variants are on opposite chromosomes, and regardless of the paternal variants, a fetus with four pathogenic variants (Hb Barts) is not possible. Hb H remains possible depending on the genotype of the partner.
        </p>
        <p>
        </p>
        <p>
         Pregnancies with severe variants are at greater risk of having an affected fetus, and individuals who carry an alpha
         <sup>
          0
         </sup>
         genotype (aa/--) are at risk for having a child with alpha thalassemia major. They may elect:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preimplantation genetic testing (PGT) on embryos created by in vitro fertilization (IVF). (See
         <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">
          "Preimplantation genetic testing"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Donor oocytes or donor sperm. (See
         <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">
          "In vitro fertilization: Overview of clinical issues and questions", section on 'Oocyte donation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7423.html" rel="external">
          "Donor insemination"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adoption. (See
         <a class="medical medical_review" href="/z/d/html/2854.html" rel="external">
          "Adoption"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prenatal testing with intensive monitoring and in utero treatment if needed. (See
         <a class="medical medical_review" href="/z/d/html/131582.html" rel="external">
          "Alpha thalassemia major: Prenatal and postnatal management", section on 'Prenatal'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4227388748">
         <span class="h1">
          RELATIVES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relatives may benefit from knowing about a thalassemia diagnosis (including carrier state) to avoid routine iron supplementation based on the mistaken impression that microcytosis is due to iron deficiency, and for reproductive counseling  (
         <a class="graphic graphic_algorithm graphicRef140056" href="/z/d/graphic/140056.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H199450933">
         <span class="h1">
          RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H2872944037">
         <span class="h2">
          UpToDate topics
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thalassemias
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7131.html" rel="external">
          "Molecular genetics of the thalassemia syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7090.html" rel="external">
          "Pathophysiology of thalassemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7116.html" rel="external">
          "Diagnosis of thalassemia (adults and children)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7118.html" rel="external">
          "Management of thalassemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/131582.html" rel="external">
          "Alpha thalassemia major: Prenatal and postnatal management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other alpha globin disorders
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7086.html" rel="external">
          "Unstable hemoglobin variants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">
          "Methemoglobinemia", section on 'Hemoglobin M disease and cytochrome b5 deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1795327586">
         <span class="h2">
          Locating a testing laboratory
         </span>
         <span class="headingEndMark">
          —
         </span>
         The table lists hemoglobinopathy testing laboratories  (
         <a class="graphic graphic_table graphicRef139930" href="/z/d/graphic/139930.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H4138428472">
         <span class="h2">
          Locating a specialist
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics professionals
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinical geneticists – American College of Medical Genetics and Genomics (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=138739" target="_blank">
          ACMG
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Genetic counselors – National Society of Genetic Counselors (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=138739" target="_blank">
          NSGC
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alpha thalassemia experts
         </strong>
         – The Thalassemia International Federation provides a list of specialty centers worldwide. The Cooley's Anemia Foundation website lists selected
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thalassemia.org%2Fwp-content%2Fuploads%2F2022%2F08%2FTTC-Map-August-29-2022-Full-List-hi-res.pdf&amp;token=i5HAXUUhTeHSQjHCXvWCERSaMar9pOI9zfGJRZEEQ3gcsNGr%2FWPbFV4wqb8CdWReuU8kKIymmvW9%2BBWc1nWJ94X5HtQVZeU2jMCjx82jx9Kw5M8oybDnLgDaEIJTX26w&amp;TOPIC_ID=138739" target="_blank">
          thalassemia centers in the United States
         </a>
         [
         <a href="#rid6">
          6
         </a>
         ]. These organizations provide educational materials and other resources. Other experts are available outside these centers.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piel FB, Weatherall DJ. The α-thalassemias. N Engl J Med 2014; 371:1908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vijian D, Wan Ab Rahman WS, Ponnuraj KT, et al. Molecular Detection of Alpha Thalassemia: A Review of Prevalent Techniques. Medeni Med J 2021; 36:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harteveld CL, Achour A, Arkesteijn SJG, et al. The hemoglobinopathies, molecular disease mechanisms and diagnostics. Int J Lab Hematol 2022; 44 Suppl 1:28.
          </a>
         </li>
         <li class="breakAll">
          Prenatal Screening for Hemoglobinopathies. UCSF Fetal Treatment Center. Available at: https://fetus.ucsf.edu/uploads/FTC-prenatal_screening_for_thalassemia.pdf (Accessed on October 03, 2022).
         </li>
         <li class="breakAll">
          Selected Thalassemia Treatment Centers. Cooley's Anemia Foundation. Available at: https://www.thalassemia.org/wp-content/uploads/2022/08/TTC-Map-August-29-2022-Full-List-hi-res.pdf (Accessed on October 03, 2022).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 138739 Version 2.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25390741" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Theα-thalassemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34915685" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Molecular Detection of Alpha Thalassemia: A Review of Prevalent Techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36074711" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The hemoglobinopathies, molecular disease mechanisms and diagnostics.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
